# The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation

## TL;DR

This editorial reviews major advances in childhood histiocytosis, especially LCH, over the past decade, focusing on genetics, therapies, and diagnostics.

## Contribution

The paper offers a comprehensive overview of transformative developments in LCH research and clinical care from 2015 to 2025.

## Key findings

- Molecular genetics has significantly improved the classification and understanding of LCH.
- Targeted therapies and refined diagnostics have enhanced patient outcomes and management strategies.
- Ongoing challenges and future research directions in LCH are identified for continued progress.

## Abstract

Over the past decade, the field of childhood histiocytosis, particularly Langerhans cell histiocytosis (LCH), has undergone transformative changes. The integration of molecular genetics, targeted therapies, and refined diagnostic methodologies has revolutionized patient management and redefined disease classification. This editorial provides a comprehensive overview of the pivotal developments from 2015 to 2025, highlights ongoing challenges, and explores future directions in research and clinical care.